Browsing: Weight Loss

As interest in gut-first weight management support grows in 2026, this Hello100 GLP-1 Booster review examines the brand-stated Akkermansia, artichoke-derived inulin, and B-vitamin formula, why its stimulant-free daily approach is attracting wellness-focused buyers, and the pricing, subscription, ingredient, and return-policy details to review before ordering

Chandler physician and IntraCare President Dr. Andrew Carroll warns against a social media trend joking about using Cyclospora for weight loss as local cases reach 36

The development of dual agonists for the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) has been a landmark moment in the treatment of type 2 diabetes and obesity. However, for reasons that are incompletely understood, in preclinical and clinical studies, adding either a GIPR agonist or GIPR antagonist to GLP-1R agonism causes…

Eli Lilly LLY announced positive top-line data from two late-stage studies evaluating its next-generation, experimental triple-acting incretin, retatrutide, in patients with obesity or those who are overweight as well as some of its most serious complications – type II diabetes and established cardiovascular disease

Millions of seniors who use GLP-1 drugs for weight loss — or want to try them but can’t afford the cost — may soon get some financial relief

This is a paid press release. Contact the press release distributor directly with any enquiries.

A Michigan man is headed to prison for selling misbranded weight loss drugs imported from China, federal prosecutors said. 

Eating one avocado per day may reduce heart disease risk in adults with obesity, according to a study by researchers at Penn State published in the Journal of Clinical Lipidology

Novo Nordisk (NYSE:NVO) has asked a U.S. court to issue a preliminary injunction that would immediately block a series of weight-loss and diabetes drug advertisements from Eli Lilly (NYSE:LLY), intensifying the legal dispute between the two pharmaceutical companies

Novo Nordisk said on Friday it is ​seeking a preliminary U.S. ​court injunction to immediately block ​obesity and diabetes drug advertisements by Eli Lilly